Description

Indication & Scope

Ikervis® | ZiRun® is a prescription ophthalmic calcineurin inhibitor indicated for the treatment of severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes.

Mechanism: Ciclosporin is a calcineurin inhibitor and topical immunomodulator that suppresses T-cell activation and inflammatory cytokine release on the ocular surface, reducing inflammation and promoting healing of the damaged corneal epithelium.
Drug class: Calcineurin inhibitor; Ophthalmic immunomodulator.
Clinical use: Anti-inflammatory treatment of severe keratitis associated with dry eye disease in adults whose condition has not improved with artificial tears.

Specification

Generic Name	Ciclosporin Ophthalmic Emulsion
Brand Name	Ikervis®, ZiRun®
Ingredient	Ciclosporin
Dosage Form	Eye Drops
Package	0.3 mL: 0.3 mg (0.1%) / single dose container, 30 containers per carton 0.4mL: 0.2mg(0.05%) / single dose container, 30 containers per carton
Conditions Treated	Severe dry eye disease with keratitis
Taboos	Hypersensitivity to ciclosporin or any component of the product
Place of origin	France, China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store at 8–30°C. Protect from light. Keep unused single-dose containers in the original foil pouch. Do not freeze.
Manufacturer	EXCELVISION, France \| Shenyang Xingqi Pharmaceutical Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	HJ20220043, H20203239
Date of Revision	April 29, 2022 \| April 09, 2025
Shelf Life	36 months, 18 months

How to use ?

Recommended Dose: Instill one drop into the affected eye(s) once daily at bedtime.

Time: Administer once every evening before bedtime. If both eyes are affected, instill one drop into each eye. Do not use a double dose if a dose is missed.

Instructions for use: For ophthalmic use only. Ikervis® is supplied in single-dose containers intended for one-time use only. Discard the container immediately after administration, even if some emulsion remains. When using other ophthalmic medications, allow an interval of at least 15 minutes between applications, and administer Ikervis® last. Patients should be re-evaluated periodically to determine the need for continued treatment.

Interaction: No clinically significant systemic drug interactions have been reported following topical ophthalmic administration. Caution is advised when Ikervis® is used concomitantly with topical corticosteroids or systemic immunosuppressive agents because additive immunosuppressive effects may occur.

Side effects: Common adverse reactions include eye pain, instillation site irritation, burning or stinging sensation, foreign body sensation, conjunctival hyperemia, increased lacrimation, ocular pruritus, and transient blurred vision. Less common reactions include blepharitis, punctate keratitis, photophobia, worsening dry eye symptoms, headache, rash, and other mild ocular discomfort.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is Ikervis® used for?

Ikervis® is indicated for the treatment of severe keratitis associated with dry eye disease in adults whose symptoms have not improved despite treatment with artificial tears.

How often should Ikervis® be used?

The recommended dosage is one drop into the affected eye(s) once daily at bedtime.

Can Ikervis® be used with artificial tears?

Yes. Artificial tears may be used during treatment, but they should be administered at least 15 minutes before Ikervis®, which should always be applied last.

Is each Ikervis® container reusable?

No. Each single-dose container is intended for one-time use only and should be discarded immediately after administration, even if some solution remains.